FAIR ACT

Key Points

• This bill creates a reciprocal approval system so the FDA can quickly approve drugs that are already authorized in trusted countries like the UK, Canada, or the European Union. Instead of going through the full FDA review process from scratch, drug companies can submit proof of foreign approval and get a decision within 30 days.
• The fast-track approval only applies to treatments for immediately life-threatening diseases or conditions. This is not a blanket shortcut for all drugs. It is meant for patients who are facing serious, urgent health situations and may have few or no other treatment options available.
• Trusted international regulators include the European Medicines Agency, the UK's MHRA, and Health Canada. The Secretary of Health and Human Services can also designate additional agencies as trusted authorities in the future.
• The bill also makes it easier to run clinical trials in the U.S. by letting researchers use approvals they already received from trusted foreign regulators. The FDA must decide within 30 days whether to allow such trials, cutting through paperwork that can slow down access to cutting-edge research.
• The FDA keeps the power to pull any drug off the market if new evidence shows it is dangerous. The agency can require post-market studies and can immediately stop marketing and distribution if serious problems appear within the first 30 days of approval.
• Congress cites concerns that the U.S. is falling behind other nations, especially China, in biopharmaceutical development and clinical trials. The bill is positioned as a way to keep the U.S. competitive while helping patients get faster access to medicines.